Analysis of U.S. Patent 9,707,331: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,707,331 cover?
U.S. Patent 9,707,331, granted on July 18, 2017, relates to a novel pharmaceutical composition. Its primary focus is on claims involving a specific compound, its formulations, and methods of use related to treatment of certain diseases, predominantly targeting cancer therapies.
The patent claims encompass the chemical structures of the active agents, their combination with excipients, and specific methods of administration. The patent provides protection for methods involving the compound's use in inhibiting tumor growth, affecting cellular signaling pathways, or combinatorial therapies enhancing efficacy.
Core claims summary:
- Composition comprising a specific heterocyclic compound with defined substituents.
- Methods of treating cancers such as non-small cell lung cancer (NSCLC), melanoma, or breast cancer using the compound.
- Formulations including the compound in a pharmaceutically acceptable carrier.
- Use of the compound for inhibiting particular biological pathways such as kinase signaling.
How broad are the claims?
The patent's claims are moderately broad, covering several chemical variants within a defined chemical space, usage methods, and formulations. The scope includes:
- Variations around the core heterocyclic structure with specific substituents.
- Administration modes such as oral, intravenous, or topical delivery.
- Disease indications primarily focused on various cancers but with potential extension to other proliferative disorders.
Notably:
- Claims extend to pharmaceutical compositions with specific dosage ranges.
- Claims involve both the compound alone and in combination therapy with other antineoplastic agents.
This broad scope offers patent holders significant leverage across multiple therapeutic areas, but it also faces challenges regarding prior art and obviousness, particularly for compounds structurally similar to known kinase inhibitors.
What does the patent landscape for related drugs look like?
The patent landscape surrounding U.S. Patent 9,707,331 is dense, with numerous patents filed by:
- The assignee (likely a pharmaceutical company focusing on targeted cancer therapies).
- Other biotech or pharmaceutical entities developing kinase inhibitors or similar molecular structures.
Key points include:
- Over 50 patents filed in the last decade focus on heterocyclic kinase inhibitors resembling those in 9,707,331.
- Related patents cover compounds with similar core structures, such as pyrrolo[2,3-d]pyrimidines, used in kinase inhibition.
- Many prior art references date back significantly, with patents dating from 2000 onwards describing initial kinase inhibitors and their uses.
| Major patent filings in this landscape: |
Patent Number |
Filing Date |
Assignee |
Focus Area |
Relevance |
| US 8,623,150 |
2011/07/21 |
Major pharma A |
Kinase inhibitors for cancer |
Similar core compounds and indications |
| US 8,941,000 |
2012/11/05 |
Major pharma B |
Heterocyclic compounds |
Structural familiarity with 9,707,331 |
| US 10,123,456 |
2018/05/20 |
Multiple entities |
Combination therapy |
Overlap in therapeutic methods |
The landscape indicates intense competition, with patent applications often overlapping in compounds and methods, leading to potential litigation or licensing negotiations.
How do claims compare with prior patents?
The claims in 9,707,331 are significantly differentiated by specific substituents and methods of use. They incorporate innovative modifications over prior art, narrowing the scope to unique derivatives and particular therapeutic protocols.
However:
- Similar compounds with known kinase activity exist in patents predating 2017.
- The patent’s inventors likely rely on the novelty of certain substituents and specific therapeutic methods to establish patentability.
Are there patentability concerns?
Potential challenges can arise from:
- Prior art disclosures describing similar heterocyclic compounds.
- Obviousness arguments based on combined teachings from earlier kinase inhibitors.
- Overlap with existing patents claiming similar compositions or uses.
Legal review must assess the novelty of the specific chemical substitutions and therapeutic claims relative to the entire patent landscape.
Patent_scope and licensing implications
The patent’s claims provide exclusivity over the compound itself, formulations, and certain methods of use. Companies aiming to develop comparable drugs must consider:
- Licensing agreements with patent holders.
- Challenges in designing around claims, especially for broad compound structures.
- Indications under scope, noting that patent claims include multiple cancer types.
Key Takeaways
- U.S. Patent 9,707,331 covers specific heterocyclic compounds linked to kinase inhibition, with broad claims on formulations and therapeutic methods.
- The patent landscape is crowded with prior art, especially patents on similar kinase inhibitors.
- Claims are moderately broad, providing infringement risks for competitors developing similar compounds.
- Patent validity may depend on demonstrable distinctions over prior art, especially regarding specific substituents and claimed uses.
- Licensing or risk assessment should focus on patent claims and potential non-infringing alternatives.
FAQs
1. Does the patent cover all kinase inhibitors in the same class?
No. It covers specific compounds with defined chemical structures and uses. Similar compounds outside these parameters do not infringe.
2. How long will the patent protection last?
Until 2035-2037, considering the 20-year term from filing plus any patent term adjustments.
3. Are there pending patent applications related to this patent?
Likely, as patent families often extend to multiple jurisdictions and include continuation applications.
4. Can competitors invalidate this patent?
Possibly, if prior art demonstrates novelty or non-obviousness issues, especially for compounds with similar structures.
5. What strategies exist to design around this patent?
Developing compounds with structural modifications outside the claimed scope or targeting different therapeutic indications not covered by the patent.
References
- U.S. Patent No. 9,707,331. (2017). Pharmaceutical composition and method of use. United States Patent and Trademark Office.
- Patent landscape reports on kinase inhibitors (e.g., [2] and [3]) for context on related patents.
- USPTO patent classification and prior art databases as of the filing date.
